Navigation Links
Tengion to Present at 27th Annual JP Morgan Healthcare Conference
Date:1/6/2009

Completed Phase 2 Bladder Augment Trial and Plans for Registration Trial to be Discussed

Breakthrough in Kidney Regeneration Program: Preclinical Progress to be Highlighted

EAST NORRITON, Pa., Jan. 6 /PRNewswire/ -- Tengion Inc., a clinical-stage organ regeneration company with products in urologic, vascular, and renal regeneration, today announced that Steven Nichtberger, M.D., president and chief executive officer, is scheduled to present at the 27th Annual JP Morgan Healthcare Conference on Monday, January 12, 2009 at 2:30 p.m. PST. The conference will be held January 12 - 15 at The Westin St. Francis Hotel in San Francisco.

For the first time, Dr. Nichtberger will discuss Tengion's completion of its Phase 2 clinical trial in patients with neurogenic bladder due to spina bifida and the company's plans for a Phase 3 trial of its Tengion Neo-Bladder Augment(R) in patients with neurogenic bladder, planned for initiation in the first half of 2009. Dr. Nichtberger will also present breakthrough preclinical data from Tengion's renal program.

"Regenerative medicine is on the verge of unimagined breakthroughs. Similar to the emergence of novel chemical, protein, and antibody therapeutics in the past few decades, the impact of regenerative medicine on human health is emerging with great promise in the new millennium," said Dr. Nichtberger. "Tengion is at the forefront of this space with a practical and proven organ regeneration technology platform with nearly a decade of human clinical experience. Recent preclinical advances in our renal program, which is focused on eliminating the need for dialysis in patients with emerging kidney failure, reinforce the promise and value of our technology platform. The past year has been filled with important milestones that position us well for 2009."

"Kidney regeneration from patients' own cells would become the standard of care for chronic renal failure therapy. Tengion's work on the neo-kidney is an important early step towards this goal," said Brian Pereira, MD, former President of the National Kidney Foundation, editor of the leading textbook, "Chronic Kidney Disease, Dialysis, & Transplantation," and Board member of Tengion, Inc.

About Tengion

Tengion is a clinical-stage organ regeneration company with products in urologic, vascular and renal regeneration based on its proprietary Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion is a fully-integrated organization, with scalable U.S. and European manufacturing and distribution capabilities, experienced research, development, clinical and commercial teams, and significant intellectual property. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information, please visit www.tengion.com.


'/>"/>
SOURCE Tengion
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
5. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
6. AtriCure to Present at Roth Capital Partners 2007 New York Conference
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. MDS to Present at Thomas Weisel Partners Healthcare Conference
9. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
10. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Sean Fay ... Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold ... any other marketer in the last 25 years. , Now, due to changes in ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The John P. ... technology that allows anyone, anywhere to track their cognitive health, and share results with ... their own brain health on the museum's website. , BrainCheck founder, Dr. David Eagleman, ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... they are seeking public support to bring their novel lifesaving device for the ... device packed with medical-grade sensors, specially designed to read a child’s vital signs, ...
(Date:4/24/2017)... Ga. (PRWEB) , ... April 24, 2017 , ... ... trusted advisor within the telehealth industry, announces the company’s VideoMedicine mobile platform has ... care providers. Available 24 hours a day, Quick Care provides patients with the ...
(Date:4/24/2017)... NEW PORT RICHEY, Fla. (PRWEB) , ... April ... ... Disease Control and Prevention (CDC), rising prescription opioid overdose deaths now claim the ... (DEA) has slashed its civil case filings against drug manufacturers, distributors, pharmacies and ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology: